Enterprise Value
429.6B
Cash
3.725B
Avg Qtr Burn
N/A
Short % of Float
0.77%
Insider Ownership
0.15%
Institutional Own.
84.00%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Jaypirca (pirtobrutinib) Details Blood cancer, Cancer, Lymphoma, Mantle cell lymphoma | Approved Quarterly sales | |
Jardiance® (empagliflozin) (anti-SGLT2) Details Diabetes, Type 2 diabetes | PDUFA Approval decision | |
Mirikizumab Details Ulcerative colitis | BLA Resubmission | |
Donanemab Details Alzheimer's disease | NDA Submission | |
Mirikizumab Details Crohns disease | Phase 3 Data readout | |
Abemaciclib Details Castration-resistant prostate cancer | Phase 3 Data readout | |
Tirzepatide Details Obesity | Phase 3 Data readout | |
Verzenio® (Abemaciclib ) Details Cancer, Breast cancer | Phase 3 Update | |
Lebrikizumab Details Skin disease/disorder, Atopic dermatitis | Phase 3 Update | |
Mirikizumab (Pediatric) Details Ulcerative colitis | Phase 2 Update | |
Peresolimab /LY3462817 Details Rheumatoid arthritis, Autoimmune disease | Phase 2 Update | |
AK-OTOF Details OTOF-mediated hearing loss | Phase 1 Update |